Target Information
Target General Infomation | |||||
---|---|---|---|---|---|
Target ID |
T91661
|
||||
Former ID |
TTDR00529
|
||||
Target Name |
Adenosine kinase
|
||||
Gene Name |
ADK
|
||||
Synonyms |
AK; Adenosine 5'-phosphotransferase; ADK
|
||||
Target Type |
Clinical Trial
|
||||
Disease | Convulsions [ICD9: 780.3; ICD10: R56.0] | ||||
Epileptic seizures [ICD9: 345.9, 780.3; ICD10: G40, P90, R56] | |||||
Epilepsy [ICD10: G40] | |||||
Pain [ICD9: 338, 356.0, 356.8,780; ICD10: G64, G90.0, R52, G89] | |||||
Function |
Atp dependent phosphorylation of adenosine and other related nucleoside analogs to monophosphate derivatives. Serves as a potential regulator of concentrations of extracellular adenosine and intracellular adenine nucleotides.
|
||||
BioChemical Class |
Kinase
|
||||
Target Validation |
T91661
|
||||
UniProt ID | |||||
EC Number |
EC 2.7.1.20
|
||||
Sequence |
MAAAEEEPKPKKLKVEAPQALRENILFGMGNPLLDISAVVDKDFLDKYSLKPNDQILAED
KHKELFDELVKKFKVEYHAGGSTQNSIKVAQWMIQQPHKAATFFGCIGIDKFGEILKRKA AEAHVDAHYYEQNEQPTGTCAACITGDNRSLIANLAAANCYKKEKHLDLEKNWMLVEKAR VCYIAGFFLTVSPESVLKVAHHASENNRIFTLNLSAPFISQFYKESLMKVMPYVDILFGN ETEAATFAREQGFETKDIKEIAKKTQALPKMNSKRQRIVIFTQGRDDTIMATESEVTAFA VLDQDQKEIIDTNGAGDAFVGGFLSQLVSDKPLTECIRAGHYAASIIIRRTGCTFPEKPD FH |
||||
Drugs and Mode of Action | |||||
Inhibitor | 5'-iodotubercidin | Drug Info | [536049] | ||
5-iodo,5'-deoxytubercidin | Drug Info | [528569] | |||
6-Benzylthioinosine | Drug Info | [530903] | |||
A-134974 | Drug Info | [525955] | |||
ABT-702 | Drug Info | [532399] | |||
GP-3269 | Drug Info | [527887] | |||
GP-683 | Drug Info | [534462] | |||
GP515 | Drug Info | [535091] | |||
Iodotubercidin | Drug Info | [531635] | |||
MB-03966 | Drug Info | [544076] | |||
Target Expression Profile (TEP) and Drug Resistance Mutation (DRM) | |||||
TEP | EXP Info | ||||
Pathways | |||||
BioCyc Pathway | Superpathway of purine nucleotide salvage | ||||
Adenine and adenosine salvage II | |||||
KEGG Pathway | Purine metabolism | ||||
Metabolic pathways | |||||
Reactome | Purine salvage | ||||
WikiPathways | Metabolism of nucleotides | ||||
References | |||||
Ref 468194 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5130). | ||||
Ref 468195 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5131). | ||||
Ref 527887 | Adenosine kinase inhibitors. 6. Synthesis, water solubility, and antinociceptive activity of 5-phenyl-7-(5-deoxy-beta-D-ribofuranosyl)pyrrolo[2,3-d]pyrimidines substituted at C4 with glycinamides andrelated compounds. J Med Chem. 2005 Dec 1;48(24):7808-20. | ||||
Ref 545930 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005394) | ||||
Ref 546153 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800006618) | ||||
Ref 525955 | Effects of A-134974, a novel adenosine kinase inhibitor, on carrageenan-induced inflammatory hyperalgesia and locomotor activity in rats: evaluation of the sites of action. J Pharmacol Exp Ther. 2001Feb;296(2):501-9. | ||||
Ref 527887 | Adenosine kinase inhibitors. 6. Synthesis, water solubility, and antinociceptive activity of 5-phenyl-7-(5-deoxy-beta-D-ribofuranosyl)pyrrolo[2,3-d]pyrimidines substituted at C4 with glycinamides andrelated compounds. J Med Chem. 2005 Dec 1;48(24):7808-20. | ||||
Ref 528569 | J Med Chem. 2006 Nov 16;49(23):6726-31.Crystal structures of human adenosine kinase inhibitor complexes reveal two distinct binding modes. | ||||
Ref 530903 | Bioorg Med Chem. 2010 May 15;18(10):3403-12. Epub 2010 Apr 8.Structure-activity relationships of carbocyclic 6-benzylthioinosine analogues as subversive substrates of Toxoplasma gondii adenosine kinase. | ||||
Ref 531635 | Therapeutic target database update 2012: a resource for facilitating target-oriented drug discovery. Nucleic Acids Res. 2012 Jan;40(Database issue):D1128-36. | ||||
Ref 532399 | ABT-702, an adenosine kinase inhibitor, attenuates inflammation in diabetic retinopathy. Life Sci. 2013 Jul 30;93(2-3):78-88. | ||||
Ref 534462 | The effect of GP683, an adenosine kinase inhibitor, on the desflurane anesthetic requirement in dogs. Anesth Analg. 1997 Sep;85(3):675-80. | ||||
Ref 535091 | Adenosine kinase inhibitor GP515 improves experimental colitis in mice. J Pharmacol Exp Ther. 2001 Jan;296(1):99-105. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.